U.S. stock night trading opening fluctuations: NextCure fell 5.43% in night trading; Coherent Corp. fell 3.29% in night trading

U.S. Stock Night Market Opening Movements

NextCure fell 5.43% in after-hours trading. Based on recent key news:

1. On July 14, NextCure announced a merger with Avere Therapeutics, causing its stock price to surge by 201.83%. After the merger, NextCure shareholders will only hold 1.21% of the shares, while Avere shareholders will hold 98.79%. This transaction raised concerns about shareholder equity dilution, leading to stock price fluctuations.

2. On July 14, the merger deal between NextCure and Avere was investigated by several law firms, questioning the merger terms' disadvantage to shareholders. The news of the investigation put pressure on the stock price, with a market value of less than $10 million.

3. On July 14, NextCure announced the merger agreement with Avere, where Avere will receive exclusive licensing for IL-23 receptor antagonists, with the transaction expected to be completed in the second half of 2026, driving the stock price up. The biotechnology industry has been volatile recently, requiring attention to policy changes.

Coherent Corp. fell 3.29% in after-hours trading. Based on recent news:

1. On July 13, Coherent announced the advantages of its technology stack and supply chain. Despite demonstrating its problem-solving capabilities in technical challenges, the market reacted lukewarmly, leading to a decline in stock price.

2. On July 15, Simply Wall St published an article about quantum computing companies and technological breakthroughs, which mentioned the industry's prospects but failed to boost Coherent's stock price.

3. On July 13, 24/7 Wall St. mentioned that Nvidia-supported companies are good buying opportunities, but it did not have a positive impact on Coherent. The quantum computing industry has broad prospects but is experiencing significant short-term volatility.

Top Gaining Stocks in U.S. Night Market

AtaiBeckley surged 65.86% in after-hours trading. Based on recent news:

1. On July 15, Bloomberg reported that Eli Lilly is negotiating to acquire psychedelic drug manufacturer AtaiBeckley, with the deal potentially being announced as early as this week. This news caused AtaiBeckley's stock price to soar by 66% in after-hours trading.

2. On July 15, AtaiBeckley has risen 31% year-to-date, with a market value of $1.97 billion as of Wednesday's close. Eli Lilly is negotiating at a premium, further driving up the stock price.

3. On July 15, U.S. President Trump ordered health regulators to expedite reviews of psychedelic drug treatments and increase federal funding for related research. This policy support also boosted AtaiBeckley's stock price. The psychedelic drug industry has recently received policy support, and market sentiment is positive.

EOS Energy rose 13.50% in after-hours trading. Based on recent key news:

1. On July 15, Eos Energy Enterprises announced a strategic partnership with the U.S. Department of Defense, securing the Golden Dome for America contract. This contract involves providing long-duration energy storage support, driving up the stock price.

2. On July 15, Eos Energy Enterprises stated that it would provide its Z3 zinc-based long-duration energy storage technology as an initial prototype to enhance the resilience of defense infrastructure, further boosting market confidence.

3. On July 15, Eos Energy Enterprises' CEO Michelle Buczkowski stated that the company has made significant progress in building relationships and technology validation over the past year, and this contract reflects the results of those efforts. The defense contract enhances market confidence and drives up the stock price.

Triller rose 7.81% in after-hours trading. Based on recent key news:

1. On July 15, DJS Law Firm announced the initiation of a securities fraud investigation into Triller Group Inc., focusing on whether the company made misleading statements or failed to disclose important information. This news has drawn market attention and may affect investor confidence.

2. On July 9, the Nasdaq Hearings Panel granted Triller an exemption, requiring it to maintain a closing price of at least $1.00 for 20 consecutive trading days before July 30. This move provides the company with an opportunity to regain compliance, potentially boosting the stock price.

3. On June 25, Triller announced it would acquire a significant position in SpaceX as a strategic financial asset. This move is seen as an important step in the company's transformation and may enhance market expectations for its future development. The market is taking a wait-and-see approach to Triller's capital operations